



IN THE CLAIMS

1. (Currently Amended) The Nneuroactive substance characterised in that it complies with comprising the formula (0)




wherein R1, R2, R3 and R4 are identical or different and are methyl or ethyl radicals.

2. (Currently Amended) The Nneuroactive substance according to claim 1 characterised in that it complies with comprising the formula (I)



3. (Currently Amended) The Nneuroactive substance according to claim 2 characterised in that it consists of comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




4. (Currently Amended) The Substance according to claim 3 characterised in that it is extracted from the Cnidarian *Rhytisma fulvum*.

5. (Currently Amended) The Substance according to claim 1, ~~2 or 3~~ characterised in that it is produced by chemical synthesis.


6-13 (Cancelled)

14. (New) A pharmacological reagent comprising the formula (0)




wherein R1, R2, R3 and R4 are methyl or ethyl radicals.

15. (New) The pharmacological reagent according to claim 14 comprising the formula (I)




16. (New) The pharmacological reagent according to claim 15 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




17. (New) The pharmacological reagent of claim 14 comprising a selective transient low voltage activated calcium membrane channel activator.


18. (New) The pharmacological reagent according to claim 14 comprising the formula (I).



19. (New) The pharmacological reagent according to claim 15 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydehydronaphthalene according to formula (II)




20. (New) An insecticide comprising the formula (0)




wherein R1, R2, R3 and R4 are methyl or ethyl radicals.

21. (New) The insecticide according to claim 1 comprising the formula (I)




22. (New) The insecticide according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




23. (New) The insecticide of claim 20 and further comprising another different insecticide.


24. (New) The insecticide according to claim 1 comprising the formula (I)



25. (New) The insecticide according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




26. (New) A medicinal product for treating neuronal excitability disorders comprising the formula (0)




wherein R₁, R₂, R₃ and R₄ are methyl or ethyl radicals.

27. (New) A medicinal product for treating neuronal excitability disorders according to claim 1 comprising the formula (I)




28. (New) A medicinal product for treating neuronal excitability disorders according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




29. (New) The medicinal product of claim 26 comprising a dopaminergic neuron activator medicinal product.

30. (New) A medicinal product for treating neuronal excitability disorders according to claim 1 comprising the formula (I)




31. (New) A medicinal product for treating neuronal excitability disorders according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)




32. (New) The medicinal product of claim 29 effective to treat Parkinson's disease.

33. (New) A medicinal product for treating neuronal excitability disorders according to claim 1 comprising the formula (I)




34. (New) A medicinal product for treating neuronal excitability disorders according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)



35. (New) The medicinal product of claim 26 effective to treat the decrease in the action potential frequency of pacemaker activity neurons.

36. (New) A medicinal product for treating neuronal excitability disorders according to claim 1 comprising the formula (I)



37. (New) A medicinal product for treating neuronal excitability disorders according to claim 2 comprising 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-acetoxydecahydronaphthalene according to formula (II)

